{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:11:00Z","timestamp":1793909460803,"version":"4.8.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:00:00Z","timestamp":1711152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:00:00Z","timestamp":1711152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Natioinal Institutes of Health Intramural Research Program, NCI"},{"name":"National Institutes of Health Intramural Research Program, NCI"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Identifying sex differences in outcomes and toxicity between males and females in oncology clinical trials is important and has also been mandated by National Institutes of Health policies. Here we analyze the Trialtrove database, finding that, strikingly, only 472\/89,221 oncology clinical trials (0.5%) had curated post-treatment sex comparisons. Among 288 trials with comparisons of survival, outcome, or response, 16% report males having statistically significant better survival outcome or response, while 42% reported significantly better survival outcome or response for females. The strongest differences are in trials of EGFR inhibitors in lung cancer and rituximab in non-Hodgkin\u2019s lymphoma (both favoring females). Among 44 trials with side effect comparisons, more trials report significantly lesser side effects in males (<jats:italic>N<\/jats:italic>\u2009=\u200922) than in females (<jats:italic>N<\/jats:italic>\u2009=\u200913). Thus, while statistical comparisons between sexes in oncology trials are rarely reported, important differences in outcome and toxicity exist. These considerable outcome and toxicity differences highlight the need for reporting sex differences more thoroughly going forward.<\/jats:p>","DOI":"10.1038\/s41467-024-46945-x","type":"journal-article","created":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T09:02:39Z","timestamp":1711184559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Outcome differences by sex in oncology clinical trials"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5284-721X","authenticated-orcid":false,"given":"Ashwin V.","family":"Kammula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2147-8033","authenticated-orcid":false,"given":"Alejandro A.","family":"Sch\u00e4ffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padma Sheila","family":"Rajagopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-1214","authenticated-orcid":false,"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7862-3940","authenticated-orcid":false,"given":"Eytan","family":"Ruppin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,23]]},"reference":[{"key":"46945_CR1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/509282a","volume":"509","author":"JA Clayton","year":"2014","unstructured":"Clayton, J. A. & Collins, F. S. Policy: NIH to balance sex in cell and animal studies. Nature 509, 282\u2013283 (2014).","journal-title":"Nature"},{"key":"46945_CR2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1096\/fj.15-279554","volume":"30","author":"JA Clayton","year":"2016","unstructured":"Clayton, J. A. Studying both sexes: a guiding principle for biomedicine. FASEB J. 30, 519\u2013524 (2016).","journal-title":"FASEB J."},{"key":"46945_CR3","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1200\/JCO.2018.78.3290","volume":"36","author":"BC \u00d6zdemir","year":"2018","unstructured":"\u00d6zdemir, B. C., Csajka, C., Dotto, G. P. & Wagner, A. D. Sex differences in efficacy and toxicity of systemic treatments: An undervalued issue in the era of precision oncology. J. Clin. Oncol. 36, 2680\u20132683 (2018).","journal-title":"J. Clin. Oncol."},{"key":"46945_CR4","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1124\/pharmrev.120.000206","volume":"73","author":"F Mauvais-Jarvis","year":"2021","unstructured":"Mauvais-Jarvis, F. et al. Sex- and gender-based pharmacological response to drugs. Pharm. Rev. 73, 730\u2013762 (2021).","journal-title":"Pharm. Rev."},{"key":"46945_CR5","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.541","volume":"7","author":"AM Moyer","year":"2019","unstructured":"Moyer, A. M., Matey, E. T. & Miller, V. M. Individualized medicine: Sex, hormones, genetics, and adverse drug reactions. Pharm. Res. Perspect. 7, e00541 (2019).","journal-title":"Pharm. Res. Perspect."},{"key":"46945_CR6","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.05.014","volume":"175","author":"CM Madla","year":"2021","unstructured":"Madla, C. M. et al. Let\u2019s talk about sex: Differences in drug therapy in males and females. Adv. Drug Deliv. Rev. 175, 113804 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"46945_CR7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. Nat. Rev. Immunol. 16, 626\u2013638 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"46945_CR8","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.775","volume":"9","author":"SC Trenaman","year":"2021","unstructured":"Trenaman, S. C., Bowles, S. K., Andrew, M. K. & Goralski, K. The role of sex, age and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs. Pharm. Res. Perspect. 9, e00775 (2021).","journal-title":"Pharm. Res. Perspect."},{"key":"46945_CR9","volume":"2011","author":"OP Soldin","year":"2011","unstructured":"Soldin, O. P., Chung, S. H. & Mattison, D. R. Sex differences in drug disposition. J. Biomed. Biotechnol. 2011, 187103 (2011).","journal-title":"J. Biomed. Biotechnol."},{"key":"46945_CR10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41568-021-00348-y","volume":"21","author":"S Haupt","year":"2021","unstructured":"Haupt, S., Caramia, F., Klein, S. L., Rubin, J. B. & Haupt, Y. Sex disparities matter in cancer development and therapy. Nat. Rev. Cancer 21, 393\u2013407 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"46945_CR11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.phrs.2017.04.027","volume":"121","author":"C Tannenbaum","year":"2017","unstructured":"Tannenbaum, C., Day, D. & Alliance, M. Age and sex in drug development and testing for adults. Pharm. Res. 121, 83\u201393 (2017).","journal-title":"Pharm. Res."},{"key":"46945_CR12","volume":"52","author":"J-J Chen","year":"2021","unstructured":"Chen, J.-J. et al. Family resilience, perceived social support, and individual resilience in cancer couples: Analysis using the actor-partner interdependence mediation model. Eur. J. Oncol. Nurs. 52, 101932 (2021).","journal-title":"Eur. J. Oncol. Nurs."},{"key":"46945_CR13","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/ACM.0000000000002027","volume":"93","author":"SE Geller","year":"2018","unstructured":"Geller, S. E. et al. The more things change, the more they stay the same: A study to evaluate compliance with inclusion and assessment of women and minorities in randomized controlled trials. Acad. Med. 93, 630\u2013635 (2018).","journal-title":"Acad. Med."},{"key":"46945_CR14","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1007\/s00432-022-04270-0","volume":"149","author":"V Arciero","year":"2023","unstructured":"Arciero, V. et al. Do female and male patients derive similar benefits from approved systemic oncology therapies? A systematic review and meta-analysis. J. Cancer Res. Clin. Oncol. 149, 4215\u20134224 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"46945_CR15","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(18)32995-7","volume":"393","author":"CR Sugimoto","year":"2019","unstructured":"Sugimoto, C. R., Ahn, Y. Y., Smith, E., Macaluso, B. & Larivi\u00e8re, V. Factors affecting sex-related reporting in medical research: a cross-disciplinary bibliometric analysis. Lancet 393, 550\u2013559 (2019).","journal-title":"Lancet"},{"key":"46945_CR16","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/jnci\/djac092","volume":"114","author":"M Hall","year":"2022","unstructured":"Hall, M. et al. An evaluation of sex- and gender-based analyses in oncology clinical trials. J. Natl Cancer Inst. 114, 1186\u20131191 (2022).","journal-title":"J. Natl Cancer Inst."},{"key":"46945_CR17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/onco.13534","volume":"26","author":"S Mendis","year":"2021","unstructured":"Mendis, S. et al. Sex representation in clinical trials associated with FDA cancer drug approvals differs between solid and hematologic malignancies. Oncologist 26, 107\u2013114 (2021).","journal-title":"Oncologist"},{"key":"46945_CR18","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1111\/bcp.13620","volume":"84","author":"C Gispen-de Wied","year":"2018","unstructured":"Gispen-de Wied, C. & de Boer, A. Commentary on \u2018Gender differences in clinical registration trials; is there a real problem?\u2019 by Labots et al. Br. J. Clin. Pharm. 84, 1639\u20131640 (2018).","journal-title":"Br. J. Clin. Pharm."},{"key":"46945_CR19","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s41999-021-00587-0","volume":"13","author":"F Stader","year":"2022","unstructured":"Stader, F. & Marzolini, C. Sex-related pharmacokinetic differences with aging. Eur. Geriatr. Med. 13, 559\u2013565 (2022).","journal-title":"Eur. Geriatr. Med."},{"key":"46945_CR20","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/1055-9965.EPI-20-0036","volume":"29","author":"M Dong","year":"2020","unstructured":"Dong, M. et al. Sex differences in cancer incidence and survival: A pan-cancer analysis. Cancer Epidemiol. Biomark. Prev. 29, 1389\u20131397 (2020).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"46945_CR21","doi-asserted-by":"publisher","unstructured":"H\u00e4gg, S. & Jylh\u00e4v\u00e4, J. Sex differences in biological aging with a focus on human studies. Elife 10, https:\/\/doi.org\/10.7554\/eLife.63425 (2021).","DOI":"10.7554\/eLife.63425"},{"key":"46945_CR22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamaoncol.2017.4427","volume":"4","author":"CK Lee","year":"2018","unstructured":"Lee, C. K. et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: A systematic review and meta-analysis. JAMA Oncol. 4, 210\u2013216 (2018).","journal-title":"JAMA Oncol."},{"key":"46945_CR23","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s44161-022-00131-8","volume":"1","author":"D Zhernakova","year":"2022","unstructured":"Zhernakova, D. et al. Age-dependent sex differences in cardiometabolic risk factors. Nat. Cardivasc. Res. 1, 844\u2013854 (2022).","journal-title":"Nat. Cardivasc. Res."},{"key":"46945_CR24","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","volume":"19","author":"F Conforti","year":"2018","unstructured":"Conforti, F. et al. Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis. Lancet Oncol. 19, 737\u2013746 (2018).","journal-title":"Lancet Oncol."},{"key":"46945_CR25","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102881","volume":"147","author":"L De Courcy","year":"2020","unstructured":"De Courcy, L., Bezak, E. & Marcu, L. G. Gender-dependent radiotherapy: The next step in personalised medicine? Crit. Rev. Oncol. Hematol. 147, 102881 (2020).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"46945_CR26","doi-asserted-by":"publisher","unstructured":"Wilson, B. E., Nadler, M. B., Desnoyers, A., Booth, C. M. & Amir, E. Meta-analysis of sex and racial subgroup participation rates and differential treatment effects for trials in solid tumor malignancies leading to US Food and Drug Administration registration between 2010 and 2021. Cancer, https:\/\/doi.org\/10.1002\/cncr.35035 (2023).","DOI":"10.1002\/cncr.35035"},{"key":"46945_CR27","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/jnci\/djz094","volume":"111","author":"F Conforti","year":"2019","unstructured":"Conforti, F. et al. Sex-based heterogeneity in response to lung cancer immunotherapy: A systematic review and meta-analysis. J. Natl Cancer Inst. 111, 772\u2013781 (2019).","journal-title":"J. Natl Cancer Inst."},{"key":"46945_CR28","doi-asserted-by":"publisher","unstructured":"Irelli, A., Sirufo, M. M., D\u2019Ugo, C., Ginaldi, L. & De Martinis, M. Sex and gender influences on cancer mmunotherapy response. Biomedicines 8, https:\/\/doi.org\/10.3390\/biomedicines8070232 (2020).","DOI":"10.3390\/biomedicines8070232"},{"key":"46945_CR29","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ccell.2022.06.005","volume":"40","author":"L Pala","year":"2022","unstructured":"Pala, L. et al. Sex and cancer immunotherapy: Current understanding and challenges. Cancer Cell 40, 695\u2013700 (2022).","journal-title":"Cancer Cell"},{"key":"46945_CR30","doi-asserted-by":"publisher","unstructured":"Raskin, J. et al. New implications of patients\u2019 sex in today\u2019s lung cancer management. Cancers 14, https:\/\/doi.org\/10.3390\/cancers14143399 (2022).","DOI":"10.3390\/cancers14143399"},{"key":"46945_CR31","doi-asserted-by":"crossref","DOI":"10.1186\/s40001-022-00789-7","volume":"27","author":"K Takada","year":"2022","unstructured":"Takada, K. et al. Association between sex and outcomes in patients with non-small-cell lung cancer receiving combination chemoimmunotherapy as a first-line therapy: a systematic review and meta-analysis of randomized clinical trials. Eur. J. Med. Res. 27, 157 (2022).","journal-title":"Eur. J. Med. Res."},{"key":"46945_CR32","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamaoncol.2018.5904","volume":"5","author":"CJD Wallis","year":"2019","unstructured":"Wallis, C. J. D. et al. Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis. JAMA Oncol. 5, 529\u2013536 (2019).","journal-title":"JAMA Oncol."},{"key":"46945_CR33","volume":"11","author":"Y Ye","year":"2020","unstructured":"Ye, Y. et al. Sex-associated molecular differences for cancer immunotherapy. Nat. Commun. 11, 1779 (2020).","journal-title":"Nat. Commun."},{"key":"46945_CR34","doi-asserted-by":"crossref","unstructured":"Frega, S. et al. Sex-based heterogeneity in non-small cell lung cancer (NSCLC) and response to immune checkpoint inhibitors (ICIs): a narrative review. Prec. Cancer Med. 4, 26 (2021).","DOI":"10.21037\/pcm-21-7"},{"key":"46945_CR35","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000796","volume":"5","author":"N Mederos","year":"2020","unstructured":"Mederos, N., Friedlaender, A., Peters, S. & Addeo, A. Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer. ESMO Open 5, e000796 (2020).","journal-title":"ESMO Open"},{"key":"46945_CR36","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11096-022-01395-7","volume":"44","author":"C Chen","year":"2022","unstructured":"Chen, C., Zhang, C., Jin, Z., Wu, B. & Xu, T. Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system. Int J. Clin. Pharm. 44, 689\u2013697 (2022).","journal-title":"Int J. Clin. Pharm."},{"key":"46945_CR37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2019.08.010","volume":"121","author":"M Davidson","year":"2019","unstructured":"Davidson, M. et al. Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials. Eur. J. Cancer 121, 40\u201347 (2019).","journal-title":"Eur. J. Cancer"},{"key":"46945_CR38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tips.2009.12.001","volume":"31","author":"TJ Nicolson","year":"2010","unstructured":"Nicolson, T. J., Mellor, H. R. & Roberts, R. R. A. Gender differences in drug toxicity. Trends Pharm. Sci. 31, 108\u2013114 (2010).","journal-title":"Trends Pharm. Sci."},{"key":"46945_CR39","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.2002.20.6.1491","volume":"20","author":"JA Sloan","year":"2002","unstructured":"Sloan, J. A. et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J. Clin. Oncol. 20, 1491\u20131498 (2002).","journal-title":"J. Clin. Oncol."},{"key":"46945_CR40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/157016307781115485","volume":"4","author":"J Wang","year":"2007","unstructured":"Wang, J. & Huang, Y. Pharmacogenomics of sex difference in chemotherapeutic toxicity. Curr. Drug Discov. Technol. 4, 59\u201368 (2007).","journal-title":"Curr. Drug Discov. Technol."},{"key":"46945_CR41","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/jnci\/djaa124","volume":"113","author":"AD Wagner","year":"2021","unstructured":"Wagner, A. D. et al. Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34\u2009640 Patients in the ACCENT Database. J. Natl Cancer Inst. 113, 400\u2013407 (2021).","journal-title":"J. Natl Cancer Inst."},{"key":"46945_CR42","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00228-022-03332-z","volume":"78","author":"G Wabont","year":"2022","unstructured":"Wabont, G., Bergeron, S., Gautier, S. & Barus, R. Sex differences in serious adverse drug reactions in patients receiving immunotherapy, targeted therapy, or chemotherapy: a disproportionality analysis of the VigiBase\u00ae. Eur. J. Clin. Pharm. 78, 1355\u20131356 (2022).","journal-title":"Eur. J. Clin. Pharm."},{"key":"46945_CR43","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/2168479018782885","volume":"53","author":"S Stergiopoulos","year":"2019","unstructured":"Stergiopoulos, S., Getz, K. A. & Blazynski, C. Evaluating the completeness of ClinicalTrials.gov. Ther. Innov. Regul. Sci. 53, 307\u2013317 (2019).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"46945_CR44","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-022-03450-3","volume":"20","author":"M Saad","year":"2022","unstructured":"Saad, M. et al. Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. J. Transl. Med. 20, 253 (2022).","journal-title":"J. Transl. Med."},{"key":"46945_CR45","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cmet.2016.05.019","volume":"23","author":"SN Austad","year":"2016","unstructured":"Austad, S. N. & Fischer, K. E. Sex differences in lifespan. Cell Metab. 23, 1022\u20131033 (2016).","journal-title":"Cell Metab."},{"key":"46945_CR46","doi-asserted-by":"crossref","DOI":"10.3389\/fragi.2023.1172789","volume":"4","author":"M Knufinke","year":"2023","unstructured":"Knufinke, M., MacArthur, M. R., Ewald, C. Y. & Mitchell, S. J. Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review. Front. Aging 4, 1172789 (2023).","journal-title":"Front. Aging"},{"key":"46945_CR47","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1740774520984866","volume":"18","author":"KJ Brand","year":"2021","unstructured":"Brand, K. J., Hapfelmeier, A. & Haller, B. A systematic review of subgroup analyses in randomised clinical trials in cardiovascular disease. Clin. Trials 18, 351\u2013360 (2021).","journal-title":"Clin. Trials"},{"key":"46945_CR48","doi-asserted-by":"crossref","first-page":"c117","DOI":"10.1136\/bmj.c117","volume":"340","author":"X Sun","year":"2010","unstructured":"Sun, X., Briel, M., Walter, S. D. & Guyatt, G. H. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 340, c117 (2010).","journal-title":"BMJ"},{"key":"46945_CR49","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMsr077003","volume":"357","author":"R Wang","year":"2007","unstructured":"Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J. & Drazen, J. M. Statistics in medicine\u2013reporting of subgroup analyses in clinical trials. N. Engl. J. Med. 357, 2189\u20132194 (2007).","journal-title":"N. Engl. J. Med."},{"key":"46945_CR50","doi-asserted-by":"crossref","first-page":"920","DOI":"10.21037\/tlcr-21-1013","volume":"11","author":"Y Huang","year":"2022","unstructured":"Huang, Y., Cho, H. J., Stranger, B. E. & Huang, R. S. Sex dimorphism in response to targeted therapy and immunotherapy in non-small cell lung cancer patients: a narrative review. Transl. Lung Cancer Res. 11, 920\u2013934 (2022).","journal-title":"Transl. Lung Cancer Res."},{"key":"46945_CR51","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1200\/JCO.2014.58.1736","volume":"33","author":"CK Lee","year":"2015","unstructured":"Lee, C. K. et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: A meta-analysis. J. Clin. Oncol. 33, 1958\u20131965 (2015).","journal-title":"J. Clin. Oncol."},{"key":"46945_CR52","volume":"3","author":"JA Pinto","year":"2018","unstructured":"Pinto, J. A. et al. Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? ESMO Open 3, e000344 (2018).","journal-title":"ESMO Open"},{"key":"46945_CR53","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.3389\/fonc.2020.01531","volume":"10","author":"J Xiao","year":"2020","unstructured":"Xiao, J., Zhou, L., He, B. & Chen, Q. Impact of Sex and Smoking on the Efficacy of EGFR-TKIs in Terms of Overall Survival in Non-small-Cell Lung Cancer: A Meta-Analysis. Front. Oncol. 10, 1531 (2020).","journal-title":"Front. Oncol."},{"key":"46945_CR54","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","volume":"7","author":"Y-L Zhang","year":"2016","unstructured":"Zhang, Y.-L. et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 7, 78985\u201378993 (2016).","journal-title":"Oncotarget"},{"key":"46945_CR55","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.21037\/jtd-20-287","volume":"12","author":"J Domagala-Kulawik","year":"2020","unstructured":"Domagala-Kulawik, J. & Trojnar, A. Lung cancer in women in 21th century. J. Thorac. Dis. 12, 4398\u20134410 (2020).","journal-title":"J. Thorac. Dis."},{"key":"46945_CR56","doi-asserted-by":"crossref","first-page":"e0038","DOI":"10.5041\/RMMJ.10172","volume":"5","author":"N Horesh","year":"2014","unstructured":"Horesh, N. & Horowitz, N. A. Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy. Rambam Maimonides Med. J. 5, e0038 (2014).","journal-title":"Rambam Maimonides Med. J."},{"key":"46945_CR57","doi-asserted-by":"publisher","unstructured":"Fresneau, B. et al. Investigating the heterogeneity of alkylating agents\u2019 efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study). Pediatr. Blood Cancer 64, https:\/\/doi.org\/10.1002\/pbc.26457 (2017).","DOI":"10.1002\/pbc.26457"},{"key":"46945_CR58","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4062\/biomolther.2018.103","volume":"26","author":"H-I Kim","year":"2018","unstructured":"Kim, H.-I., Lim, H. & Moon, A. Sex differences in cancer: Epidemiology, genetics and therapy. Biomol. Ther. 26, 335\u2013342 (2018).","journal-title":"Biomol. Ther."},{"key":"46945_CR59","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3324\/haematol.2019.218883","volume":"104","author":"E Lucchini","year":"2019","unstructured":"Lucchini, E., Zaja, F. & Bussel, J. Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? Haematologica 104, 1124\u20131135 (2019).","journal-title":"Haematologica"},{"key":"46945_CR60","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","volume":"119","author":"C M\u00fcller","year":"2012","unstructured":"M\u00fcller, C. et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 119, 3276\u20133284 (2012).","journal-title":"Blood"},{"key":"46945_CR61","volume":"1","author":"S Heidari","year":"2016","unstructured":"Heidari, S., Babor, T. F., De Castro, P., Tort, S. & Curno, M. Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use. Res Integr. Peer Rev. 1, 2 (2016).","journal-title":"Res Integr. Peer Rev."},{"key":"46945_CR62","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1016\/S0140-6736(16)32392-3","volume":"388","author":"L Schiebinger","year":"2016","unstructured":"Schiebinger, L., Leopold, S. S. & Miller, V. M. Editorial policies for sex and gender analysis. Lancet 388, 2841\u20132842 (2016).","journal-title":"Lancet"},{"key":"46945_CR63","doi-asserted-by":"publisher","unstructured":"Grassadonia, A. et al. Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced cancer: A systematic review and meta-analysis of phase III randomized clinical trials. J. Clin. Med. 7, https:\/\/doi.org\/10.3390\/jcm7120542 (2018).","DOI":"10.3390\/jcm7120542"},{"key":"46945_CR64","doi-asserted-by":"crossref","first-page":"15413","DOI":"10.18632\/aging.203100","volume":"13","author":"L-T Lai","year":"2021","unstructured":"Lai, L.-T. et al. Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis. Aging 13, 15413\u201315432 (2021).","journal-title":"Aging"},{"key":"46945_CR65","doi-asserted-by":"publisher","unstructured":"Wang, S., Cowley, L. A. & Liu, X.-S. Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy. Molecules 24, https:\/\/doi.org\/10.3390\/molecules24183214 (2019).","DOI":"10.3390\/molecules24183214"},{"key":"46945_CR66","doi-asserted-by":"crossref","first-page":"e2012534","DOI":"10.1001\/jamanetworkopen.2020.12534","volume":"3","author":"F Yang","year":"2020","unstructured":"Yang, F. et al. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis. JAMA Netw. Open 3, e2012534 (2020).","journal-title":"JAMA Netw. Open"},{"key":"46945_CR67","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41586-022-04833-8","volume":"606","author":"CP Vellano","year":"2022","unstructured":"Vellano, C. P. et al. Androgen receptor blockade promotes response to BRAF\/MEK-targeted therapy. Nature 606, 797\u2013803 (2022).","journal-title":"Nature"},{"key":"46945_CR68","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.drudis.2016.01.012","volume":"21","author":"M Chang","year":"2016","unstructured":"Chang, M. et al. Developing timely insights into comparative effectiveness research with a text-mining pipeline. Drug Discov. Today 21, 473\u2013480 (2016).","journal-title":"Drug Discov. Today"},{"key":"46945_CR69","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13045-022-01227-1","volume":"15","author":"D Wu","year":"2022","unstructured":"Wu, D. et al. The global landscape of neoadjuvant and adjuvant anti-PD-1\/PD-L1 clinical trials. J. Hematol. Oncol. 15, 16 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"46945_CR70","volume":"2","author":"KW Siah","year":"2021","unstructured":"Siah, K. W. et al. Predicting drug approvals: The Novartis data science and artificial intelligence challenge. Patterns 2, 100312 (2021).","journal-title":"Patterns"},{"key":"46945_CR71","doi-asserted-by":"crossref","first-page":"e2242370","DOI":"10.1001\/jamanetworkopen.2022.42370","volume":"5","author":"AV Kammula","year":"2022","unstructured":"Kammula, A. V., Sch\u00e4ffer, A. A. & Rajagopal, P. S. Characterization of oncology clinical trials using germline genetic data. JAMA Netw. Open 5, e2242370 (2022).","journal-title":"JAMA Netw. Open"},{"key":"46945_CR72","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm.4306","volume":"23","author":"SM Corsello","year":"2017","unstructured":"Corsello, S. M. et al. The Drug Repurposing Hub: a next-generation drug library and information resource. Nat. Med. 23, 405\u2013408 (2017).","journal-title":"Nat. Med."},{"key":"46945_CR73","doi-asserted-by":"publisher","unstructured":"Kammula, A. V., Sch\u00e4ffer A. A. Code repository for \u2018Outcome differences by sex in clinical trials\u2019 (this paper). Zenodo https:\/\/github.com\/ruppinlab\/ProcessTrialtrove, https:\/\/doi.org\/10.5281\/zenodo.10713794 (2023).","DOI":"10.5281\/zenodo.10713794"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46945-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46945-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46945-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T17:50:39Z","timestamp":1738259439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46945-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,23]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["46945"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-46945-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,23]]},"assertion":[{"value":"16 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.K. has received research funding from Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda, and TopAlliance and from the NCI; as well as consultant and\/or speaker fees and\/or advisory board\/consultant for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Inc., Biological Dynamics, Caris, Datar Cancer Genetics, Daiichi, EISAI, EOM Pharmaceuticals, Iylon, LabCorp, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Regeneron, Roche, TD2\/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch Inc. and IDbyDNA; serves on the Board of CureMatch and CureMetrix, and is a co-founder of CureMatch. E.R. is a co-founder of Medaware Ltd, Metabomed Ltd and of Pangea Biomed, Ltd (divested from the latter). E.R. serves as a non-paid scientific consultant to Pangea Biomed, Ltd. The other authors declare that they have no potential competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2608"}}